Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

Saadah NH, Schipperus MR, Wiersum-Osselton JC, van Kraaij MG, Caram-Deelder C, Beckers EAM, Leyte A, Rondeel JMM, de Vooght KMK, Weerkamp F, Zwaginga JJ, van der Bom JG.

Haematologica. 2019 Jul 4. pii: haematol.2019.222083. doi: 10.3324/haematol.2019.222083. [Epub ahead of print]

2.

The identification of cases of major hemorrhage during hospitalization in patients with acute leukemia using routinely recorded healthcare data.

Kreuger AL, Middelburg RA, Beckers EAM, de Vooght KMK, Zwaginga JJ, Kerkhoffs JH, van der Bom JG.

PLoS One. 2018 Aug 15;13(8):e0200655. doi: 10.1371/journal.pone.0200655. eCollection 2018.

3.

International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy.

De Vooght KMK, Lozano M, Bueno JL, Alarcón A, Romera I, Suzuki K, Zhiburt E, Holbro A, Infanti L, Buser A, Hustinx H, Deneys V, Frélik A, Thiry C, Murphy M, Staves J, Selleng K, Greinacher A, Kutner JM, Bonet Bub C, Castilho L, Kaufman RM, Colling ME, Perseghin P, Incontri A, Dassi M, Brilhante D, Macédo A, Cserti-Gazdewich C, Pendergrast JM, Hawes J, Lundgren MN, Storry JR, Jain A, Marwaha N, Sharma RR.

Vox Sang. 2018 Jun 26. doi: 10.1111/vox.12652. [Epub ahead of print] No abstract available.

PMID:
29947125
4.

Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary.

de Vooght KMK, Lozano M, Bueno JL, Alarcón A, Romera I, Suzuki K, Zhiburt E, Holbro A, Infanti L, Buser A, Hustinx H, Deneys V, Frélik A, Thiry C, Murphy M, Staves J, Selleng K, Greinacher A, Kutner JM, Bonet Bub C, Castilho L, Kaufman R, Colling ME, Perseghin P, Incontri A, Dassi M, Brilhante D, Macêdo A, Cserti-Gazdewich C, Pendergrast JM, Hawes J, Lundgren MN, Storry JR, Jain A, Marwaha N, Sharma RR.

Vox Sang. 2018 May 20. doi: 10.1111/vox.12653. [Epub ahead of print] No abstract available.

PMID:
29781081
5.

Direct costs of transfusion reactions - an expert judgement approach.

Janssen MP, van Tilborgh AJW, de Vooght KMK, Bokhorst AG, Wiersum-Osselton JC.

Vox Sang. 2018 Feb;113(2):143-151. doi: 10.1111/vox.12614. Epub 2017 Nov 9.

PMID:
29124766
6.

Age of platelet concentrates and time to the next transfusion.

Caram-Deelder C, van der Bom JG, Putter H, Leyte A, Kerkhof DV, Evers D, Beckers EA, Weerkamp F, Hudig F, Zwaginga JJ, Rondeel JMM, de Vooght KMK, Péquériaux NCV, Visser O, Wallis JP, Middelburg RA.

Transfusion. 2018 Jan;58(1):121-131. doi: 10.1111/trf.14388. Epub 2017 Oct 31.

PMID:
29090466
7.

Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients.

Caram-Deelder C, Kreuger AL, Evers D, de Vooght KMK, van de Kerkhof D, Visser O, Péquériaux NCV, Hudig F, Zwaginga JJ, van der Bom JG, Middelburg RA.

JAMA. 2017 Oct 17;318(15):1471-1478. doi: 10.1001/jama.2017.14825. Erratum in: JAMA. 2018 Feb 20;319(7):724.

8.

Storage time of platelet concentrates and all-cause bacteremia in hematologic patients.

Kreuger AL, Middelburg RA, Bank CMC, Beckers EAM, van Gammeren AJ, Leyte A, Rondeel JMM, de Vooght KMK, Weerkamp F, Zwaginga JJ, Kerkhoffs JLH, van der Bom JG.

Transfusion. 2017 Sep;57(9):2096-2103. doi: 10.1111/trf.14194. Epub 2017 Jun 26.

PMID:
28653425
9.

Absence of the spleen and the occurrence of primary red cell alloimmunization in humans.

Evers D, van der Bom JG, Tijmensen J, de Haas M, Middelburg RA, de Vooght KMK, van de Kerkhof D, Visser O, Péquériaux NCV, Hudig F, Zwaginga JJ.

Haematologica. 2017 Aug;102(8):e289-e292. doi: 10.3324/haematol.2016.162685. Epub 2017 Apr 14. No abstract available.

10.

Screening for hemosiderosis in patients receiving multiple red blood cell transfusions.

de Jongh AD, van Beers EJ, de Vooght KMK, Schutgens REG.

Eur J Haematol. 2017 May;98(5):478-484. doi: 10.1111/ejh.12858. Epub 2017 Mar 2.

PMID:
28129458
11.

New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.

De Vooght KM, Oostendorp M, van Solinge WW.

Curr Opin Hematol. 2016 Nov;23(6):557-562. Review.

PMID:
27389485
12.

Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Evers D, Zwaginga JJ, Tijmensen J, Middelburg RA, de Haas M, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, van der Bom JG.

Haematologica. 2017 Jan;102(1):52-59. doi: 10.3324/haematol.2016.152074. Epub 2016 Sep 15.

13.

Red cell alloimmunisation in patients with different types of infections.

Evers D, van der Bom JG, Tijmensen J, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Zwaginga JJ.

Br J Haematol. 2016 Dec;175(5):956-966. doi: 10.1111/bjh.14307. Epub 2016 Aug 18.

PMID:
27539877
14.

Protocol for a national blood transfusion data warehouse from donor to recipient.

van Hoeven LR, Hooftman BH, Janssen MP, de Bruijne MC, de Vooght KM, Kemper P, Koopman MM.

BMJ Open. 2016 Aug 4;6(8):e010962. doi: 10.1136/bmjopen-2015-010962.

15.

Transfusion of platelets, but not of red blood cells, is independently associated with nosocomial infections in the critically ill.

Engele LJ, Straat M, van Rooijen IHM, de Vooght KMK, Cremer OL, Schultz MJ, Bos LDJ, Juffermans NP; MARS Consortium.

Ann Intensive Care. 2016 Dec;6(1):67. doi: 10.1186/s13613-016-0173-1. Epub 2016 Jul 19.

16.

Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study.

Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Schonewille H, Zwaginga JJ, van der Bom JG.

Lancet Haematol. 2016 Jun;3(6):e284-92. doi: 10.1016/S2352-3026(16)30019-9. Epub 2016 May 9.

PMID:
27264038
17.

Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing.

De Vooght KM, Oostendorp M, van Solinge WW.

Transfusion. 2016 Mar;56(3):778-9. doi: 10.1111/trf.13474. No abstract available.

PMID:
26954457
18.

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.

Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PW, van Solinge WW, De Vooght KM.

Transfusion. 2015 Jun;55(6 Pt 2):1555-62. doi: 10.1111/trf.13150. Epub 2015 May 18.

PMID:
25988285
19.

Falsely elevated point-of-care hematocrit and calculated hemoglobin concentration due to extreme leukocytosis.

de Vooght KM, Groenendaal F, Bierings MB, van Solinge WW, Huisman A.

Ann Hematol. 2014 Nov;93(11):1949-50. doi: 10.1007/s00277-014-2092-2. Epub 2014 May 1. No abstract available.

PMID:
24782122
20.

Immunosuppressants and alloimmunization against red blood cell transfusions.

Zalpuri S, Evers D, Zwaginga JJ, Schonewille H, de Vooght KM, le Cessie S, van der Bom JG.

Transfusion. 2014 Aug;54(8):1981-7. doi: 10.1111/trf.12639. Epub 2014 Apr 1.

PMID:
24689865
21.

Analysis of bloodgas, electrolytes and glucose from intraosseous samples using an i-STAT(®) point-of-care analyser.

Veldhoen ES, de Vooght KM, Slieker MG, Versluys AB, Turner NM.

Resuscitation. 2014 Mar;85(3):359-63. doi: 10.1016/j.resuscitation.2013.12.002. Epub 2013 Dec 31.

PMID:
24389357
22.

Reply: Concepts of arterial oxygen saturation in the presence of carboxyhemoglobin.

Kemperman H, van Solinge WW, Hol S, van der Spoel JI, de Vooght KM.

Am J Respir Crit Care Med. 2013 Sep 15;188(6):750. doi: 10.1164/rccm.201302-0393LE. No abstract available.

PMID:
24032385
23.

Storage time of red blood cell concentrates and adverse outcomes after cardiac surgery: a cohort study.

Voorhuis FT, Dieleman JM, de Vooght KM, van Dijk D, van Herwerden LA, Peelen LM, van Klei WA.

Ann Hematol. 2013 Dec;92(12):1701-6. doi: 10.1007/s00277-013-1832-z. Epub 2013 Jul 7.

PMID:
23832235
24.

Feasibility of point-of-care creatinine testing in community pharmacy to monitor drug therapy in ambulatory elderly patients.

Geerts AF, De Koning FH, De Vooght KM, Egberts AC, De Smet PA, van Solinge WW.

J Clin Pharm Ther. 2013 Oct;38(5):416-22. doi: 10.1111/jcpt.12081. Epub 2013 Jun 28.

PMID:
23808548
25.

Intensive red blood cell transfusions and risk of alloimmunization.

Zalpuri S, Middelburg RA, Schonewille H, de Vooght KM, le Cessie S, van der Bom JG, Zwaginga JJ.

Transfusion. 2014 Feb;54(2):278-84. doi: 10.1111/trf.12312. Epub 2013 Jun 19.

PMID:
23782244
26.

Extracellular vesicles in the circulation: are erythrocyte microvesicles a confounder in the plasma haemoglobin assay?

de Vooght KM, Lau C, de Laat PP, van Wijk R, van Solinge WW, Schiffelers RM.

Biochem Soc Trans. 2013 Feb 1;41(1):288-92. doi: 10.1042/BST20120254. Review.

PMID:
23356299
27.

A 56-year-old man with an apparently normal oxygen saturation and a dead canary.

Hol S, de Vooght KM, van der Spoel JJ, van Solinge WW, Kemperman H.

Am J Respir Crit Care Med. 2012 Nov 1;186(9):928-9. No abstract available.

PMID:
23118086
28.

Persistent A-antigen after stem cell transplantation of blood group A patient with non-A donor.

de Vooght KM, Schutgens RE, van Solinge WW.

Am J Hematol. 2012 Nov;87(11):E118-9. doi: 10.1002/ajh.23310. Epub 2012 Aug 1.

29.

Hypothermic cardiopulmonary bypass surgery in a 7-year-old boy with a cold agglutinin.

Hubeek I, ter Heide H, van Solinge WW, de Vooght KM.

Ann Hematol. 2012 Dec;91(12):1989-90. doi: 10.1007/s00277-012-1515-1. Epub 2012 Jul 5. No abstract available.

PMID:
22763946
30.

A role for activated endothelial cells in red blood cell clearance: implications for vasopathology.

Fens MH, van Wijk R, Andringa G, van Rooijen KL, Dijstelbloem HM, Rasmussen JT, de Vooght KM, Schiffelers RM, Gaillard CA, van Solinge WW.

Haematologica. 2012 Apr;97(4):500-8. doi: 10.3324/haematol.2011.048694. Epub 2011 Nov 18.

31.

Successful transfusion care for a patient with the Rhesus -D- phenotype and antibodies against Rh17 and two additional alloantibodies.

De Vooght KM, Demir AY, Folman CC, Schutgens RE, van Solinge WW, Kemperman H.

Ann Hematol. 2012 Jun;91(6):963-4. doi: 10.1007/s00277-011-1344-7. No abstract available.

32.

Visualizing veins with near-infrared light to facilitate blood withdrawal in children.

Cuper NJ, Verdaasdonk RM, de Roode R, de Vooght KM, Viergever MA, Kalkman CJ, de Graaff JC.

Clin Pediatr (Phila). 2011 Jun;50(6):508-12. doi: 10.1177/0009922810395932. Epub 2011 Feb 27.

PMID:
21357203
33.

Diagnostic accuracy and user-friendliness of 5 point-of-care D-dimer tests for the exclusion of deep vein thrombosis.

Geersing GJ, Toll DB, Janssen KJ, Oudega R, Blikman MJ, Wijland R, de Vooght KM, Hoes AW, Moons KG.

Clin Chem. 2010 Nov;56(11):1758-66. doi: 10.1373/clinchem.2010.147892. Epub 2010 Sep 15.

34.

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W.

Rheumatology (Oxford). 2010 Mar;49(3):441-9. doi: 10.1093/rheumatology/kep418. Epub 2009 Dec 17.

PMID:
20019066
35.

First mutation in the red blood cell-specific promoter of hexokinase combined with a novel missense mutation causes hexokinase deficiency and mild chronic hemolysis.

de Vooght KM, van Solinge WW, van Wesel AC, Kersting S, van Wijk R.

Haematologica. 2009 Sep;94(9):1203-10. doi: 10.3324/haematol.2008.002881. Epub 2009 Jul 16.

36.

Gene promoter analysis in molecular diagnostics: do or don't?

de Vooght KM, van Solinge WW.

Expert Rev Mol Diagn. 2009 Jul;9(5):403-5. doi: 10.1586/erm.09.28. Review. No abstract available.

PMID:
19580424
37.

Management of gene promoter mutations in molecular diagnostics.

de Vooght KM, van Wijk R, van Solinge WW.

Clin Chem. 2009 Apr;55(4):698-708. doi: 10.1373/clinchem.2008.120931. Epub 2009 Feb 26. Review.

38.

Blood gas values during hypothermia in asphyxiated term neonates.

Groenendaal F, De Vooght KM, van Bel F.

Pediatrics. 2009 Jan;123(1):170-2. doi: 10.1542/peds.2008-1955. Review. No abstract available.

PMID:
19117878
39.

Characterization of the -148C>T promoter polymorphism in PKLR.

de Vooght KM, van Wijk R, van Wesel AC, van Solinge WW.

Haematologica. 2008 Sep;93(9):1407-8. doi: 10.3324/haematol.12328. Epub 2008 Aug 12. No abstract available.

40.

GATA-1 binding sites in exon 1 direct erythroid-specific transcription of PPOX.

de Vooght KM, van Wijk R, van Solinge WW.

Gene. 2008 Feb 15;409(1-2):83-91. doi: 10.1016/j.gene.2007.11.010. Epub 2007 Dec 4.

PMID:
18191920
41.

A family with multiple mutations and sequence variations in the alpha- and beta-globin gene clusters.

de Vooght KM, van Wijk R, Rijksen G, van Solinge WW.

Clin Chem Lab Med. 2008;46(2):165-8.

PMID:
18076350
42.

Characterization of the -16C>G sequence variation in the promoters of both HBG1 and HBG2: convergent evolution of the human gamma-globin genes.

de Vooght KM, van Wijk R, Ploos van Amstel HK, van Solinge WW.

Blood Cells Mol Dis. 2007 Jul-Aug;39(1):70-4. Epub 2007 Apr 25.

PMID:
17462922
43.

Pyruvate kinase regulatory element 1 (PKR-RE1) mediates hexokinase gene expression in K562 cells.

de Vooght KM, van Wijk R, van Oirschot BA, Rijksen G, van Solinge WW.

Blood Cells Mol Dis. 2005 Mar-Apr;34(2):186-90.

PMID:
15727904
44.

[From gene to disease; hereditary non-spherocytic hemolytic anemia caused by pyruvate kinase deficiency].

de Vooght KM, van Wijk R, Nieuwenhuis HK, Ploos van Amstel JK, Rijksen G, van Solinge WW.

Ned Tijdschr Geneeskd. 2002 Sep 28;146(39):1828-31. Dutch.

PMID:
12382367

Supplemental Content

Loading ...
Support Center